NCT06125080View on ClinicalTrials.gov

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

Utidelone

Utidelone (30 mg/m2, days 1-5, every 3 weeks)

DRUG

Tirelizumab

Tirelizumab（200mg, day1, every 3 weeks）

DRUG

Bevacizumab

Bevacizumab(7.5mg/kg, day1, every 3 weeks)

Trial Locations (1)

430000

RECRUITING

Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Huihua Xiong

OTHER

NCT06125080 - The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study | Biotech Hunter | Biotech Hunter